EUVIMEDEUVIMED entdecken
Crossref

Sequential Moderate Hypofractionated Boost in Breast Cancer Patients: A Monoinstitutional Analysis of Late Side Effects

Isabella Palumbo, Anna Giulia Becchetti, Elisabetta Perrucci, Lorenzo Falcinelli, Simonetta Saldi, Vittorio Bini, Cynthia Aristei

Anticancer Research · 2024

DOI: 10.21873/anticanres.17225 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2024. Verfasst von Isabella Palumbo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Radiation Oncology Section, University of Perugia and Perugia General Hospital, Perugia, Italy; isabella.palumbo@unipg.it. Hauptthemen laut MEDLINE: Breast Neoplasms, Radiation Dose Hypofractionation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: In breast cancer (BC) patients who have received breast-conserving surgery, moderate hypofractionation is standard of care for whole-breast irradiation (HF-WBI). On the other hand, the fractionation schedule for the boost is less well defined. A previous prospective study of our group aimed at evaluating acute and late cutaneous and subcutaneous side effects related to a sequential hypofractionated boost (HB) in patients who had received HF-WBI. The present study aimed at evaluating late side effects at a longer follow-up. PATIENTS AND METHODS: From 2014 to 2015, 219 BC patients received moderate HF-WBI (42.4 Gy in 16 fractions) at the Radiation Oncology Section of the University of Perugia. Patients with negative prognostic factors received a HB (2.65 Gy for 4 or 5 fractions). Late side effects were assessed using the Common Terminology Criteria for Adverse Events v5.0. Univariate and multivariate analyses estimated predictive factors for late toxicity. RESULTS: Median follow-up was 8.6 years (range=6.7-9.6). One hundred and sixty-five patients were evaluable in the present analysis; HB was administered to 47.3% of them. Late cutaneous and subcutaneous side effects occurred in 26/165 patients (15.8%); and all were G1. In univariate analysis ≥10 excised lymph nodes and HB administration emerged as risk factors for late side effects (p=0.003 and p=0.041, respectively). In multivariate analysis only ≥10 excised lymph nodes were confirmed as a risk factor for side effects (OR=3.431; 95%CI=1.209-9.737). CONCLUSION: HB after HF-WBI was safe and well-tolerated, even at a long-term follow-up; consequently, it can be used in routine practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsRadiation Dose HypofractionationHumansFemaleMiddle AgedAgedAdultAged, 80 and overFollow-Up StudiesDose Fractionation, RadiationProspective StudiesMastectomy, SegmentalRadiation Injuries

Stichwörter der Autor:innen

Breast cancercutaneous side-effectsmoderate hypofractionated boostmoderate hypofractionated whole breast radiotherapysequential boostsubcutaneous side-effects

Autor:innen und Institutionen

  • Radiation Oncology Section, University of Perugia and Perugia General Hospital, Perugia, Italy; isabella.palumbo@unipg.it.
  • Radiation Oncology Section, University of Perugia, Perugia, Italy.
  • Radiation Oncology Division, Perugia General Hospital, Perugia, Italy.
  • Internal Medicine Endocrine and Metabolic Science Section, University of Perugia, Perugia, Italy.
  • Radiation Oncology Section, University of Perugia and Perugia General Hospital, Perugia, Italy.

Zitieren

APA

Palumbo, I., Becchetti, A. G., Perrucci, E., Falcinelli, L., Saldi, S., Bini, V., & Aristei, C. (2024). Sequential Moderate Hypofractionated Boost in Breast Cancer Patients: A Monoinstitutional Analysis of Late Side Effects. Anticancer Research. https://doi.org/10.21873/anticanres.17225

Vancouver

Palumbo I, Becchetti AG, Perrucci E, Falcinelli L, Saldi S, Bini V, et al. Sequential Moderate Hypofractionated Boost in Breast Cancer Patients: A Monoinstitutional Analysis of Late Side Effects. Anticancer Research. 2024. doi:10.21873/anticanres.17225

BibTeX
@article{Palumbo2024,
  author = {Palumbo, Isabella and Becchetti, Anna Giulia and Perrucci, Elisabetta and Falcinelli, Lorenzo and Saldi, Simonetta and Bini, Vittorio and Aristei, Cynthia},
  title = {Sequential Moderate Hypofractionated Boost in Breast Cancer Patients: A Monoinstitutional Analysis of Late Side Effects},
  journal = {Anticancer Research},
  year = {2024},
  doi = {10.21873/anticanres.17225}
}
Kostenlos starten →